about
Biomarkers and echocardiographic predictors of myocardial dysfunction in patients with hypertension.Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study.Statins and dilated cardiomyopathy: do we have enough data?The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe.Malignancy-associated dyslipidemia.Redo surgery risk in patients with cardiac prosthetic valve dysfunction.Biological artificial valve dysfunction - single-centre, observational echocardiographic study in patients operated on before age 65 years.The multi-biomarker approach for heart failure in patients with hypertension.The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up.The mechanisms of atrial fibrillation in hyperthyroidismNew methods in laboratory diagnostics of dilated cardiomyopathy.Takotsubo cardiomyopathy--the current state of knowledge.What is the risk of hyperkalaemia in heart failure?The meaning of hypokalemia in heart failure.An update on biomarkers of heart failure in hypertensive patients.The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction.The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy.The effects of statins on blood pressure in normotensive or hypertensive subjects--a meta-analysis of randomized controlled trials.Sources of thromboembolism in patients with correctly functioning mechanical valves: a single-center transesophageal echocardiographic study.Heart failure biomarkers in patients with dilated cardiomyopathy.Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies.Novel drugs for heart rate control in heart failure.Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure[Proinflammatory cytokines in cardiovascular diseases as potential therapeutic target]HSP 70 and atherosclerosis--protector or activator?Current place of beta-blockers in the treatment of hypertensionThe unligated left internal mammary artery side branch as the cause of angina after coronary artery bypass graftingEstablished and potential echocardiographic markers of embolism and their therapeutic implications in patients with ischemic strokeFind the Essence through the Phenomena: Cardiovascular Diseases and BiomarkersSubclinical hypothyroidism and the development of heart failure: an overview of risk and effects on cardiac functionAssociation of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysisThe Role of Adipokines in the Development of Arterial Stiffness and Hypertension
P50
Q33559608-3CEBB71D-2C4E-46C9-8B63-EAD1F9661151Q33711829-155399B5-FDA4-4360-A7BC-77DF31254A9CQ33787152-307056D5-64DD-4E82-8847-A583113693B4Q34746089-26509A52-89F0-4DF7-BCCC-753A34B3E7D0Q35030677-5020EFC6-906A-44FC-995B-D3BFF2236241Q35674059-93A35808-96EE-4342-A948-333F7F8E6224Q35691376-16E91CE3-A5EC-4B21-B1EF-721F1DE1FF1FQ35723466-BD33C94F-1EB7-4D56-B08D-96D8DEFBAE3EQ36811609-F04BD4D8-8615-4C4C-9851-A4B69D04981AQ37188729-F7F1CB2E-9060-40AC-B1CA-4799EFD7303DQ37242503-7920AB2E-71DB-42A1-BDC9-60EEF66DE14CQ37668800-CFFE05E2-D982-4F89-A509-284E40D763A4Q37902667-4CBF8C8C-9075-4C6D-817C-E1D81A641663Q37903098-6EBD1F6F-1BC0-4626-BE2E-7E96D5429E06Q38029164-C9B288C9-C6E4-409D-8846-D54F7D7FB4C1Q38615348-963BE9E7-4A4F-46B5-8E9E-A5BE24AD3FB4Q43234015-24238B51-89BA-43D3-9BF1-F0FD7268E3E8Q44751016-AB1E5576-93EE-4338-9DCF-9D26562DB2A9Q45395577-40E75188-8513-4ABB-A497-9DCC3DFDB7FEQ48160359-D6B3C296-0A2B-4DB8-B1D8-DD694E4FA26FQ48608419-BB776555-6725-4D92-8091-14C44C8E2C41Q51732936-53025B8F-D0B3-4A5D-A1FD-153206CD13FFQ55610979-CE611FF2-06C5-41B0-867A-F5021CEB6DBBQ56990072-46593EBC-1AB1-4182-99C3-72ACE64E56F5Q59683761-23CFEC13-006C-4B21-A4DF-97B4D3CDC1DEQ80898051-ADF2D23D-6A41-463E-AAC8-AD12657CFFBBQ83390162-5089ABDE-FB38-4DE7-B148-A676E037CE7BQ84564330-697D48FA-B7FB-4F70-822C-127A89DFEBC5Q84861022-65E68F05-D6EC-4A5A-AD70-9F7E71898D10Q88541932-5C67D617-D730-4DC9-B91E-0A555ED9149CQ90402613-42CEFB38-FD95-4BE3-B405-109D1AD1646AQ90847730-CEB2E63F-6CF9-4A16-8EFB-3BACE537DE92Q91041084-05B9139C-59CF-4D36-B1D4-DD200B806C17Q95284384-63C30472-860A-413B-B92C-6A20BC6E0527
P50
description
Pools onderzoekster
@nl
researcher ORCID ID = 0000-0001-6666-3999
@en
name
Agata Bielecka-Dabrowa
@ast
Agata Bielecka-Dabrowa
@ca
Agata Bielecka-Dabrowa
@cs
Agata Bielecka-Dabrowa
@en
Agata Bielecka-Dabrowa
@es
Agata Bielecka-Dabrowa
@gl
Agata Bielecka-Dabrowa
@hr
Agata Bielecka-Dabrowa
@hsb
Agata Bielecka-Dabrowa
@it
Agata Bielecka-Dabrowa
@nl
type
label
Agata Bielecka-Dabrowa
@ast
Agata Bielecka-Dabrowa
@ca
Agata Bielecka-Dabrowa
@cs
Agata Bielecka-Dabrowa
@en
Agata Bielecka-Dabrowa
@es
Agata Bielecka-Dabrowa
@gl
Agata Bielecka-Dabrowa
@hr
Agata Bielecka-Dabrowa
@hsb
Agata Bielecka-Dabrowa
@it
Agata Bielecka-Dabrowa
@nl
altLabel
Agata Magdalena Bielecka-Dąbrowa
@pl
prefLabel
Agata Bielecka-Dabrowa
@ast
Agata Bielecka-Dabrowa
@ca
Agata Bielecka-Dabrowa
@cs
Agata Bielecka-Dabrowa
@en
Agata Bielecka-Dabrowa
@es
Agata Bielecka-Dabrowa
@gl
Agata Bielecka-Dabrowa
@hr
Agata Bielecka-Dabrowa
@hsb
Agata Bielecka-Dabrowa
@it
Agata Bielecka-Dabrowa
@nl
P106
P1153
25631942900
P1412
P1559
Agata Bielecka-Dabrowa
@pl
P21
P27
P31
P3124
P496
0000-0001-6666-3999